| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Affimed N.V (NASDAQ: AFMD)
AFMD Technical Analysis
5
| As on 19th May 2025 AFMD STOCK Price closed @ 0.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.49 & Strong Sell for SHORT-TERM with Stoploss of 0.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AFMDSTOCK Price
| Open | 0.22 | Change | Price | % |
| High | 0.24 | 1 Day | -0.10 | -35.71 |
| Low | 0.17 | 1 Week | -0.52 | -74.29 |
| Close | 0.18 | 1 Month | -0.39 | -68.42 |
| Volume | 23016664 | 1 Year | -0.34 | -65.38 |
| 52 Week High 7.33 | 52 Week Low 0.09 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| LCID | 2.16 | 5.37% |
| HCTI | 0.03 | 50.00% |
| NVDA | 159.34 | 1.33% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| PLUG | 1.47 | 5.00% |
| WINT | 0.93 | 20.78% |
| BTBT | 2.94 | 11.79% |
| LILM | 0.05 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AFMD Daily Charts |
AFMD Intraday Charts |
Whats New @ Bazaartrend |
AFMD Free Analysis |
|
|
AFMD Important Levels Intraday
| RESISTANCE | 0.31 |
| RESISTANCE | 0.27 |
| RESISTANCE | 0.24 |
| RESISTANCE | 0.22 |
| SUPPORT | 0.14 |
| SUPPORT | 0.12 |
| SUPPORT | 0.09 |
| SUPPORT | 0.05 |
AFMD Forecast July 2025
| 4th UP Forecast | 0.97 |
| 3rd UP Forecast | 0.72 |
| 2nd UP Forecast | 0.56 |
| 1st UP Forecast | 0.4 |
| 1st DOWN Forecast | -0.04 |
| 2nd DOWN Forecast | -0.2 |
| 3rd DOWN Forecast | -0.36 |
| 4th DOWN Forecast | -0.61 |
AFMD Weekly Forecast
| 4th UP Forecast | 0.45 |
| 3rd UP Forecast | 0.36 |
| 2nd UP Forecast | 0.31 |
| 1st UP Forecast | 0.26 |
| 1st DOWN Forecast | 0.10 |
| 2nd DOWN Forecast | 0.05 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | -0.09 |
AFMD Forecast2025
| 4th UP Forecast | 17.29 |
| 3rd UP Forecast | 11.8 |
| 2nd UP Forecast | 8.41 |
| 1st UP Forecast | 5.02 |
| 1st DOWN Forecast | -4.66 |
| 2nd DOWN Forecast | -8.05 |
| 3rd DOWN Forecast | -11.44 |
| 4th DOWN Forecast | -16.93 |
Affimed N.V ( NASDAQ USA Symbol : AFMD )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AFMD Business Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Address: Technologiepark, Heidelberg, Germany, 69120
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service